<DOC>
	<DOCNO>NCT01732783</DOCNO>
	<brief_summary>This multicenter , observational prospective cohort study France Germany . Treatment centre focus treat subject mCRC prospectively define potential inclusion study . Eligible subject enrol retrospective data collect Baseline point enrolment . All subsequent chemotherapy cycle Vectibix® dose record prospectively . Each subject data collect approximately 30 day end Vectibix® treatment , death , withdrawal consent , loss follow-up 12 month first dose Vectibix® , whichever occur first .</brief_summary>
	<brief_title>Observational Study Vectibix With Chemotherapy Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Subject ≥ 18 year age date enrolment Histologically cytologically confirm carcinoma colon rectum Subject metastatic carcinoma colon rectum Confirmed wildtype RAS status tumour Subjects whose care manage primarily enrol physician and/ record available Tumour assessment ( ie , CT/MRI ) within 12 week ( 84 day ) prior first Vectibix® infusion . Subjects treat least one infusion Vectibix® combination chemotherapy maximum 84 day enter study : firstline combination FOLFOX secondline combination FOLFIRI subject receive firstline fluoropyrimidinebased chemotherapy ( exclude irinotecan ) treatment wildtype RAS mCRC per approve prescribe information Subject subject 's legally acceptable representative provide informed consent ( country require per local regulation ) Subjects treat Vectibix® accordance current version SmPC Exclusion Criteria Ongoing plan concurrent participation clinical study involve Investigational Product approve European Medicines Agency indication Ongoing plan concurrent participation clinical study dose Vectibix® determine protocol ( participation clinical trial approve drug observational trial permit mandate mCRC treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Wild-type RAS</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Vectibix</keyword>
</DOC>